Poly-gamma-glutamic Acid Composition for Obesity Treatment via Gut Microbiota Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current obesity management strategies, including calorie-restricted diets and anti-obesity drugs, are ineffective and have side effects, and there is a need for safer and more effective treatments that target the gut microbiota for obesity prevention and treatment.
Innovation Solution
A composition containing poly-γ-glutamic acid (γ-PGA) isolated from Bacillus is used to suppress adipogenesis-related gene expression, reduce lipid accumulation, and regulate gut microbiota, increasing beneficial bacteria like Clostridia and decreasing harmful bacteria like Erysipelotrichia, thereby controlling obesity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Weight of moving object
If calorie-restricted diet is used for obesity management, then weight loss can be achieved, but consumer preference and acceptance decrease making it difficult to sustain long-term
Solution Approach 1:
The patent introduces poly-γ-glutamic acid (γ-PGA) as an intermediary substance that mediates between the goal of weight loss and consumer acceptance. γ-PGA acts as a functional food ingredient that naturally suppresses adipogenesis and regulates gut microbiota, providing weight management benefits without requiring restrictive dietary behavior changes, thus resolving the contradiction between effectiveness and sustainability
Solution Approach 2:
The patent employs γ-PGA to enable the body's own metabolic systems to regulate fat accumulation autonomously. By modulating gut microbiota composition and suppressing adipogenic gene expression, γ-PGA allows the body to self-regulate weight management processes without external dietary control, improving both effectiveness and long-term adherence
2Productivity
If anti-obesity drugs are used for obesity treatment, then weight loss effectiveness can be improved, but side effects such as diarrhea, oil spots, and flatulence occur
Solution Approach 1:
The patent replaces conventional anti-obesity drugs with poly-γ-glutamic acid, a biodegradable and edible polymer that functions as a short-term functional food ingredient. γ-PGA exerts its anti-obesity effects through natural biological mechanisms (adipogenesis suppression and gut microbiota modulation) rather than pharmacological intervention, providing effective weight management without the harmful side effects associated with traditional drugs
Solution Approach 2:
The patent changes the fundamental parameter of the treatment approach from pharmacological (drugs) to biochemical (natural polymer). By using γ-PGA, a biocompatible substance with different chemical properties than conventional anti-obesity medications, the patent achieves weight loss through altered metabolic regulation and microbiota modulation, eliminating the toxic side effects while maintaining therapeutic effectiveness
3Productivity
If existing obesity treatments are used, then some weight loss effect can be achieved, but safety and long-term sustainability are compromised
Solution Approach 1:
The patent employs a composite approach by combining poly-γ-glutamic acid (a biodegradable polymer) with specific gut microbiota modulation. This composite strategy integrates multiple mechanisms - adipogenesis suppression through gene expression regulation and gut microbiota composition modulation - to achieve synergistic weight management effects that are both safe and sustainable long-term
Solution Approach 2:
The patent fundamentally changes the safety parameter by transitioning from pharmacological treatments with known side effects to a biocompatible natural polymer. γ-PGA's biodegradability and edibility ensure high safety, while its dual mechanism of action (adipogenesis suppression and microbiota modulation) ensures long-term sustainability, resolving the contradiction between effectiveness, safety, and sustainability
Data Source
AI summary
An object of the present disclosure is to provide a composition for preventing or treating obesity comprising a substance isolated from poly-γ-glutamic acid (γ-PGA) as an active ingredient. According to the present disclosure, it was confirmed that γ-PGAbm or γ-PGAcm, a substance isolated from γ-PGA, suppressed the expression of adipogenic marker genes in 3T3-L1 cells to reduce accumulation of lipid droplets and triglycerides, and suppressed the expression of cell cycle regulators in the early stage of adipogenesis to reduce adipocyte differentiation. In addition, γ-PGAbm or γ-PGAcm has been confirmed to suppress obesity through weight loss, positive changes in glucose and insulin resistance, reduction of epididymal adipocytes, and suppression of adipogenesis, and thus may be used effectively for related businesses.